Achilles Therapeutics plc (NASDAQ:ACHL) Shares Bought by BML Capital Management LLC

BML Capital Management LLC boosted its holdings in shares of Achilles Therapeutics plc (NASDAQ:ACHL) by 555.8% in the 3rd quarter, Holdings Channel.com reports. The fund owned 4,100,002 shares of the company’s stock after buying an additional 3,474,828 shares during the quarter. Achilles Therapeutics makes up about 2.5% of BML Capital Management LLC’s holdings, making the stock its 11th biggest holding. BML Capital Management LLC owned approximately 0.10% of Achilles Therapeutics worth $4,182,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in the business. XTX Topco Ltd increased its stake in Achilles Therapeutics by 239.4% during the second quarter. XTX Topco Ltd now owns 51,660 shares of the company’s stock worth $42,000 after acquiring an additional 36,441 shares during the last quarter. Ikarian Capital LLC acquired a new stake in Achilles Therapeutics during the first quarter worth $1,804,000. StemPoint Capital LP acquired a new stake in shares of Achilles Therapeutics in the first quarter valued at $1,732,000. Finally, Acadian Asset Management LLC acquired a new stake in shares of Achilles Therapeutics in the first quarter valued at $350,000. Institutional investors and hedge funds own 56.38% of the company’s stock.

Achilles Therapeutics Trading Down 1.9 %

ACHL traded down $0.02 during mid-day trading on Tuesday, hitting $1.02. 40,405 shares of the stock were exchanged, compared to its average volume of 460,114. The firm’s fifty day moving average is $0.93 and its two-hundred day moving average is $0.87. Achilles Therapeutics plc has a 1-year low of $0.63 and a 1-year high of $1.76. The company has a market cap of $41.91 million, a PE ratio of -0.65 and a beta of 1.35.

Achilles Therapeutics (NASDAQ:ACHL) last announced its quarterly earnings data on Wednesday, August 14th. The company reported ($0.41) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.41). As a group, research analysts anticipate that Achilles Therapeutics plc will post -1.7 earnings per share for the current year.

About Achilles Therapeutics

Achilles Therapeutics plc, a biopharmaceutical company, develops precision T cell therapies to treat solid tumors. Its platform identifies mutations formed early in the development of cancer. The company offers PELEUS, a proprietary AI-powered bioinformatics platform, used to identify clonal neoantigens in a patient.